Market Research Report
Global Uterine Fibroids Market: Industry Analysis & Outlook 2017-2025
|Published by||Koncept Analytics||Product code||439416|
|Published||Content info||66 Pages
|Global Uterine Fibroids Market: Industry Analysis & Outlook 2017-2025|
|Published: February 10, 2017||Content info: 66 Pages||
Fibroids are tumors in the uterus which can vary in sizes depending upon the condition and level. A woman may have one or many fibroids in reproductive organ. It is common for a woman to have multiple fibroid tumors which are non-cancerous in nature. Uterine fibroids are broadly classified into four categories i.e. Subserosal fibroids, Intramural fibroids, Submucosal fibroid, and Pedunculated submucosal fibroid.
Currently, the uterine fibroid market has no definitive FDA approved agents for medical treatment of uterine leiomyomata or uterine fibroids. Gonadotropin-releasing hormone analogues (GnRHa) agents are being used to reduce size of tumor, reduce blood loss and to correct the ensuing iron-deficiency anemia.
The global uterine fibroids drugs market is expected to experience robust growth post the launch of therapeutic drugs, primarily due to increasing patient base, rise in female population, and increasing healthcare expenditure. However, the market growth is hindered by high R&D costs and regulatory warnings.
The report “Global Uterine Fibroids Drugs Market: Industry Analysis & Outlook (2017-2025)” analyzes the development of this market, with focus on the US and European markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: AbbVie, Myovant Sciences, Astra Zeneca, and Neurocrine Biosciences are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global uterine fibroids market along with the study of the regional markets.